Soleno Therapeutics Investors Face Deadline for Significant Losses

Kirby McInerney LLP reminds investors of the May 5, 2026 deadline to seek compensation.

Apr. 2, 2026 at 1:54am

Got story updates? Submit your updates here. ›

Kirby McInerney LLP has issued a reminder to investors of Soleno Therapeutics, Inc. (NASDAQ:SLNO) about the upcoming May 5, 2026 deadline to seek compensation for significant losses related to the company.

Why it matters

Soleno Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases. Investors who have experienced significant losses may be eligible for compensation, but they must act before the upcoming deadline.

The details

The law firm Kirby McInerney LLP is representing Soleno Therapeutics investors and has set a May 5, 2026 deadline for them to seek compensation for their losses. The details of the case and eligibility criteria have not been publicly disclosed.

  • The deadline to seek compensation is May 5, 2026.

The players

Kirby McInerney LLP

A law firm representing Soleno Therapeutics investors in a case related to significant losses.

Soleno Therapeutics, Inc.

A biopharmaceutical company focused on developing treatments for rare diseases.

Got photos? Submit your photos here. ›

The takeaway

This case highlights the importance for investors to stay informed and act quickly when facing significant losses, as deadlines for seeking compensation can be time-sensitive.